Prof. Huang Tang, Ph.D.,

Introduction

Prof. Tang is mainly engaged in the research of pharmacochemistry including the design, synthesis and pharmacological evaluation of new organic small molecular compounds against neurodegenerative diseases.He has presided over 7 scientific research projects (One project of the National Natural Science Foundation of China, three projects of Guangxi Natural Science Foundation and three projects at the prefectural level).More than 10 scientific research papers have been published in Eur. J. Med. Chem., Int. J. Biol. Macromol., Neurochem. Inter. and other foreign academic journals by the first author or the communication author.

Education

2004 - 2007  College of pharmacy, Sun Yat-sen University, Ph.D.

1997 - 2000  College of Chemistry and Chemical Engineering, Lanzhou University, Master

1993 - 1997  Department of Chemistry, Guangxi Normal University

Professional Experience

2012 - Current Professor , School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, China

2009 - 2011 Associate Professor , School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, China

2003 - 2008 Instructor, Department of Chemistry, Guangxi Normal University, Guilin, China

Representative achievement：

1. Wang, J., Li, W., Qin, J., Wang, L., Wei, S., Tang, Huang^*, Assessment of novel azaanthraquinone derivatives as potent multi-target inhibitors of inflammation and amyloid-beta aggregation in Alzheimer's disease. Bioorg. Chem.2019, 83, 477-486.

2. Ke-Lin Chen; Ling Gan; Zhen-Hua Wu; Jin-Fang Qin; Wen-Xia Liao; Huang Tang*,4- Substituted sampangine derivatives: Novel acetylcholinesterase and β-myloid aggregation inhibitors , Int. J. Biol. Macromol. 2018, 107: 2725~2729.

3. Zhenhua Wu ; Wenxia Liao; Kelin Chen; Jingfang Qin; Huang Tang*, Synthesis of derivatives of cleistopholine and their anti-acetylcholinesterase and anti-β-amyloid aggregation activity,Bioorg. Chem. 2018, 76: 228~236.

4. Liyingzi Huang, Yunfeng Luo, Xianghui Kong, Huanhuan Xing, Zhijun Pu, Shenqi Wei, Wei Chen*, Huang Tang*, Oxoisoaporphine alkaloid derivative 8-1 reduces Aβ1-42 secretion and toxicity in human cell and Caenorhabditis elegans models of Alzheimer’s disease, Neurochem. Int.2017, 108: 157-168.

5. Wei, Shenqi; Chen, Wei; Qin, Jingfang; Huangli, Yingzi; Wang, Li; Shen, Yue; Tang, Huang^*, Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer’s disease. Bioorg. Med. Chem., 2016, 24(22): 6031-6039.

6. Wei Chen, Yuhuan Wu, Shuming Zhong, Ling Cheng, Qinghua Li^*, Huang Tang^*. Anti-neurotoxicity effects of oxoisoaporphine-lipoic acid hybrids, Chemico-Biological Interactions 223 (2014) 45–50

7. Tang, Huang; Zhao, H.-T.; Zhong, S.-M.; Wang, Z.-Y.; Chen, Z.-F.; Liang, H., Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 2012, 22, (6), 2257-2261.

8. Tang, Huang; Zhao, L.-Z.; Zhao, H.-T.; Huang, S.-L.; Zhong, S.-M.; Qin, J.-K.; Chen, Z.-F.; Huang, Z.-S.; Liang, H., Hybrids of oxoisoaporphine-tacrine congeners: Novel acetylcholinesterase and acetylcholinesterase-induced beta -amyloid aggregation inhibitors.Eur. J. Med. Chem.2011, 46, (10), 4970-4979.

9. Tang, Huang; Wei, Y.-B.; Zhang, C.; Ning, F.-X.; Qiao, W.; Huang, S.-L.; Ma, L.; Huang, Z.-S.; Gu, L.-Q., Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase. Eur. J. Med. Chem. 2009, 44, (6), 2523-2532.

10. Tang, Huang; Wang, X.-D.; Wei, Y.-B.; Huang, S.-L.; Huang, Z.-S.; Tan, J.-H.; An, L.-K.; Wu, J.-Y.; Sun-Chi Chan, A.; Gu, L.-Q., Oxoisoaporphine alkaloid derivatives: Synthesis, DNA binding affinity and cytotoxicity. Eur. J. Med. Chem.2008, 43, (5), 973-980.